Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra) Versus Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel) in Subjects 11 to 55 Years of Age in South Korea

Trial Profile

Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra) Versus Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel) in Subjects 11 to 55 Years of Age in South Korea

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs DTaP vaccine (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Diphtheria; Meningococcal infections; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 18 Jul 2013 Planned End Date changed from 1 Nov 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top